Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8TF42

UPID:
UBS3B_HUMAN

ALTERNATIVE NAMES:
Cbl-interacting protein p70; Suppressor of T-cell receptor signaling 1; T-cell ubiquitin ligand 2; Tyrosine-protein phosphatase STS1/TULA2

ALTERNATIVE UPACC:
Q8TF42; Q53GT5; Q53GT8; Q8NBV7; Q96IG9; Q96NZ2

BACKGROUND:
The protein Ubiquitin-associated and SH3 domain-containing protein B, with alternative names such as Suppressor of T-cell receptor signaling 1, is pivotal in regulating receptor-type tyrosine kinases. By preventing CBL-mediated degradation of these receptors, it ensures their presence on the cell surface, enhancing cellular responses to external signals. Its phosphatase activity towards EGFR and other substrates underscores its regulatory function in signal transduction pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin-associated and SH3 domain-containing protein B offers a promising avenue for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.